<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-19927" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Allergic Contact Dermatitis</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Murphy</surname>
            <given-names>Patrick B.</given-names>
          </name>
          <aff>Desert Regional Medical Center</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Atwater</surname>
            <given-names>Amber R.</given-names>
          </name>
          <aff>Duke University Medical Center</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Mueller</surname>
            <given-names>Matthew</given-names>
          </name>
          <aff>University of California San Diego</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Patrick Murphy declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Amber Atwater declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Matthew Mueller declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>13</day>
          <month>7</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-19927.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Allergic contact dermatitis (ACD) is a type 4 or delayed-type hypersensitivity response (DTH) by an individual&#x02019;s immune system to a small molecule (less than 500 daltons), or hapten, that contacts a sensitized individual&#x02019;s skin. ACD accounts for 20% of contact dermatoses, and allergens differ greatly based upon geography, personal habits, and hobbies, and often, the types of preservatives that are legally permissible. This activity illustrates the etiology, pathophysiology, and highlights the role of the interprofessional team in the management of allergic contact dermatitis.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Outline the etiology of allergic contact dermatitis.</p></list-item><list-item><p>Describe the clinical presentation, workup, and management of allergic contact dermatitis.</p></list-item><list-item><p>Review that allergic contact dermatitis involves a complex interplay between biological, psychological, behavioral, and dietary factors.</p></list-item><list-item><p>Explain the role of the interprofessional team in ensuring comprehensive patient and caregiver education to achieve better clinical outcomes.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=19927&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=19927">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-19927.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Allergic contact dermatitis (ACD) is a type 4 or delayed-type hypersensitivity response (DTH) by an individual&#x02019;s immune system to a small molecule (less than 500 daltons), or hapten, that contacts a sensitized individual&#x02019;s skin.<xref ref-type="bibr" rid="article-19927.r1">[1]</xref> The initial or induction&#x000a0;phase of ACD occurs when the hapten combines with a protein to form a complex that leads to the expansion of an allergen-specific T cell population; the name for this process is sensitization.&#x000a0;During the elicitation phase, re-exposure to the antigen leads to the development of dermatitis. ACD accounts for 20% of contact dermatoses, and allergens differ greatly&#x000a0;based upon geography, personal habits, and hobbies, and&#x000a0;often, the types of&#x000a0;preservatives that are legally permissible, such as&#x000a0;quaternium-15 in the United States but not Europe.<xref ref-type="bibr" rid="article-19927.r2">[2]</xref></p>
      </sec>
      <sec id="article-19927.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Allergic contact dermatitis is an inflammatory disease of the skin that is caused by a type 4 hypersensitivity&#x000a0;reaction. It results from the contact of an offending chemical or antigen with the skin, and the subsequent T-cell mediated response.<xref ref-type="bibr" rid="article-19927.r3">[3]</xref> Morphology and location of the dermatitis are often the best indicators of the offending agent. For instance, when found around the wrist, it may indicate an allergic response to a bracelet or watchband.</p>
        <p>Poison ivy is a common cause of ACD and presents as linear streaks where the plant comes into contact with the skin.</p>
        <p>Nickel is another common cause of ACD and presents as dermatitis where necklaces and earrings containing nickel are worn.</p>
        <p>Rubber gloves are also a common cause of chronic dermatitis.</p>
        <p>Other agents include hair dyes, textile chemicals, preservatives, fragrances, sunscreens, and photo allergens.</p>
      </sec>
      <sec id="article-19927.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Allergic contact dermatitis is an inflammatory disease of the skin that is&#x000a0;common in the general population. It is the most common type of occupational skin disease.<xref ref-type="bibr" rid="article-19927.r4">[4]</xref></p>
        <p>The disorder is more common in women than in men. In the elderly, the condition often correlates with topical medications.</p>
      </sec>
      <sec id="article-19927.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>The pathophysiology of allergic contact dermatitis starts with the contact of the allergen to the skin. This allergen penetrates that stratum corneum of the skin and is taken up by Langerhans cells.<xref ref-type="bibr" rid="article-19927.r5">[5]</xref>&#x000a0;<xref ref-type="bibr" rid="article-19927.r6">[6]</xref> The antigens subsequently undergo processing by these cells and get displayed on their surface. Langerhans cells then migrate towards regional lymph nodes. The antigens taken up by these cells come in contact with the adjacent T-lymphocytes. Due to the process of clonal expansion as well as cytokine-induced&#x000a0;proliferation, antigen-specific&#x000a0;T lymphocytes get created. These lymphocytes may then travel through the blood and into the epidermis. This process collectively is known as the sensitization phase of allergic contact dermatitis. The elicitation phase is what&#x000a0;occurs after reexposure to the antigen takes place. The Langerhans cells containing the antigen interacts with the antigen-specific T-lymphocytes for that antigen, which triggers a cytokine-induced proliferation process. This proliferation, in turn, creates a localized inflammatory response.</p>
      </sec>
      <sec id="article-19927.s6" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>The diagnosis of&#x000a0;allergic contact dermatitis is usually established by a combination of history and physical examination, clinical presentation, and a positive patch test. If further evaluation is required, a skin biopsy of an affected area of skin will typically demonstrate spongiosis. However, this finding is unlikely to facilitate differentiation of ACD from other eczematous dermatologic disorders. <xref ref-type="bibr" rid="article-19927.r7">[7]</xref></p>
      </sec>
      <sec id="article-19927.s7" sec-type="Toxicokinetics">
        <title>Toxicokinetics</title>
        <p>The intensity of the inflammatory&#x000a0;response in&#x000a0;allergic contact dermatitis is dependent on both the sensitizing ability of the allergen and the concentration of the allergen present. Poison ivy is an example of a strong sensitizer that can create an intense inflammatory response, even in small concentrations.<xref ref-type="bibr" rid="article-19927.r8">[8]</xref></p>
      </sec>
      <sec id="article-19927.s8" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Obtain a thorough history of occupation, hobbies,&#x000a0; medications, lifestyle, use of fragrances, and perfumes.&#x000a0;</p>
        <p>Allergic contact dermatitis can present on physical exam as acute or chronic. Acute ACD characteristically presents as an erythematous, eczematous, or vesicular dermatitis. Although ACD may present with a localized, well-demarcated skin eruption most commonly on the hands or face, it can also be more widespread. For example, rinse-off products such as shampoo or body wash&#x000a0;may come into contact with many parts of the body, leading to a more diffuse presentation.<xref ref-type="bibr" rid="article-19927.r9">[9]</xref>&#x000a0;Additionally,&#x000a0;in cases&#x000a0;where the patient systemically consumes an allergen, a more diffuse cutaneous reaction may occur. Chronic ACD more commonly presents with lichenification, fissuring, and scale.<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmid" xlink:href="30096055">[10]</ext-link>&#x000a0;</p>
      </sec>
      <sec id="article-19927.s9" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>A good clinical evaluation of allergic contact dermatitis involves a detailed history and physical. The morphology and location of the dermatitis&#x000a0;is often the best indicator of the offending agent. Patch testing is the gold standard to confirm the diagnosis and should be performed when ACD is suspected in patients with persistent symptoms. Patch testing can help determine the allergen to avoid future exposure. While patch testing is easy to perform, the test may be over-utilized, leading to higher costs for the patient. If the diagnosis is still not certain, a skin biopsy usually demonstrates spongiosis.<xref ref-type="bibr" rid="article-19927.r10">[11]</xref></p>
        <p>One should always rule&#x000a0;out tinea as a cause of dermatitis.</p>
      </sec>
      <sec id="article-19927.s10" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>The only definitive treatment of ACD is the identification and removal of the offending agent, and all patients with suspected or confirmed ACD should be advised&#x000a0;of this. First-line medical therapy includes topical steroids when ACD is confined to less than 20% of the body, and oral corticosteroids when greater than 20% of the body is involved.&#x000a0; If ACD involves a delicate area such as skin folds or eyelids, topical calcineurin inhibitors or PDE4 inhibitors may also be effective. Upon identification of the allergen, strict avoidance is necessary to prevent a recurrence.<xref ref-type="bibr" rid="article-19927.r11">[12]</xref>&#x000a0;Symptomatic management includes oral antihistamines, topical hydrocortisone, and cool water soaks.&#x000a0;Vesicles should not be ruptured as there is a risk of infection. The use of moisturizers is a recommended adjunct.</p>
        <p>For severe cases, topical immunomodulators like tacrolimus may be beneficial. Some patients may benefit from phototherapy using UV A plus psoralen. Rarely in severe cases, one may&#x000a0;require immunosuppressive agents like mycophenolate.</p>
        <p>In cases of chronic or recalcitrant ACD, use patch testing to identifying the causative agent.<xref ref-type="bibr" rid="article-19927.r12">[13]</xref>&#x000a0;Successful patch testing requires several components: choice of appropriate&#x000a0;chemicals for testing, a positive patch test to relevant allergens, and patient counseling of patch test results. Additionally, the American Contact Dermatitis Society&#x02019;s Contact Allergen Management Program (CAMP) can be utilized to generate a &#x0201c;safe list&#x0201d; of products that do not contain the patient&#x02019;s allergens. In the case where allergens are unavoidable, systemic therapy may be necessary.<xref ref-type="bibr" rid="article-19927.r13">[14]</xref></p>
      </sec>
      <sec id="article-19927.s11" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>Morphologically the clinical presentation of allergic contact dermatitis is very similar to irritant contact dermatitis and atopic dermatitis.<xref ref-type="bibr" rid="article-19927.r14">[15]</xref>&#x000a0;Other skin conditions that should be ruled out include drug eruptions, scabies, urticarial bullous pemphigoid, urticaria, psoriasis, seborrheic dermatitis, periorificial dermatitis, and rosacea.&#x000a0;</p>
      </sec>
      <sec id="article-19927.s12" sec-type="Treatment Planning ">
        <title>Treatment Planning </title>
        <p>The goal of the treatment of allergic contact dermatitis is to decrease the inflammatory response that is triggered by the type 4 hypersensitivity reaction. Reactions caused by strong sensitizers may require quicker and more aggressive&#x000a0;treatment as the intensity of dermatitis will increase. Identifying and removing the allergen is the most effective definitive treatment. Ointment-based moisturizers and steroids are preferred vehicles of treatment as creams contain a variety of chemicals and preservatives.<xref ref-type="bibr" rid="article-19927.r15">[16]</xref></p>
      </sec>
      <sec id="article-19927.s13" sec-type="Toxicity and Adverse Effect Management">
        <title>Toxicity and Adverse Effect Management</title>
        <p>The most important step in the management of allergic contact dermatitis is the removal of the offending agent. Toxicities and adverse&#x000a0;effects to monitor are related to the treatment options. It is crucial to control the strength of the topical steroids&#x000a0;to appropriate&#x000a0;dosages as the most common adverse effect of these medications is thinning of the skin.<xref ref-type="bibr" rid="article-19927.r15">[16]</xref></p>
      </sec>
      <sec id="article-19927.s14" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>This disease stays with the affected populations throughout their lives. Strict avoidance of the allergen needs to be the implemented strategy. Management of the inflammatory response is the essential goal in treatment.<xref ref-type="bibr" rid="article-19927.r11">[12]</xref></p>
        <p>The longer&#x000a0;a person&#x000a0;has ACD, the more time it will take to resolve.</p>
      </sec>
      <sec id="article-19927.s15" sec-type="Complications">
        <title>Complications</title>
        <p>Complications associated with allergic contact dermatitis (ACD) involve the inflammatory response.<xref ref-type="bibr" rid="article-19927.r4">[4]</xref>&#x000a0;The inflammation subsides with the&#x000a0;removal of the allergen. If the allergen is consumed systemically, diffuse dermatitis might occur, but this condition is not considered a dermatologic&#x000a0;emergency.</p>
      </sec>
      <sec id="article-19927.s16" sec-type="Consultations">
        <title>Consultations</title>
        <p>Unknown causes of allergic contact dermatitis (ACD) may require patch testing, which is best performed by a&#x000a0;dermatologist, immunologist, allergist, or physician with clinical experience in analyzing and testing allergic contact dermatitis.</p>
      </sec>
      <sec id="article-19927.s17" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Educating patients on allergic contact dermatitis (ACD) involves assisting the patient in identifying their allergic triggers. Patients must then be provided with practical behavioral modifications to help decrease the inflammatory response of this disease. For instance,&#x000a0;in professions that require regular use of rubber gloves, it is essential that patients can identify the natural rubber allergy and choose a glove type that uses a rubber accelerator&#x000a0;(i.e.,&#x000a0;thiurams, carbamates, mercapto compounds) towards which they do not form a reaction.<xref ref-type="bibr" rid="article-19927.r4">[4]</xref></p>
        <p>A diet low in nickel and other minerals has been said to improve symptoms in some patients.</p>
      </sec>
      <sec id="article-19927.s18" sec-type="Pearls and Other Issues">
        <title>Pearls and Other Issues</title>
        <p>Cross-sensitization may occur in the population affected by allergic contact dermatitis (ACD). This process occurs when an antigen that is chemically&#x000a0;similar to an antigen that had previously been sensitized&#x000a0;by the host triggers a contact dermatitis. Additionally, systemically-induced allergic dermatitis&#x000a0;may take place when an individual who already has undergone sensitization to a contact allergen consumes the allergen by another route (inhalation, ingestion, injection).<xref ref-type="bibr" rid="article-19927.r16">[17]</xref></p>
      </sec>
      <sec id="article-19927.s19" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>The pharmacist is in the prime position to educate the patient on prevention. Patients should be told to avoid wearing nickel-containing jewelry, use latex-free gloves, avoid hair dyes and fragrances which trigger dermatitis. Patients should receive education about reading labels on products to ensure that they do not contain the trigger chemicals. Nurses are also in a strong position to provide counsel on these avoidance strategies.</p>
        <p>For those who have ACD of the hands, the use of latex-free gloves may help. Also, patients should use mild cleansing agents on the skin and use protective agents like emollients to help minimize symptoms.</p>
        <p>Enhancing patient outcomes is the interprofessional healthcare team's number one priority. Physicians will prescribe treatment when necessary and would do well to verify agent selection and strength with the pharmacist. Nurses should&#x000a0;monitor for compliance and also spot adverse events from treatments like topical steroids. Patients with allergic contact dermatitis must have strict return precautions and information on the natural progression of the disease. Patients should not simply receive treatment and sent out the door with a prescription. It is crucial to tailor the treatment to the patient, and the body part affected. Patients also need to have a follow-up with a specialist and continued education. It is vital to utilize nurses and ancillary staff to help communicate in a way that the patient understands. Patients should also have continuous monitoring and follow up with their primary care physician who can help coordinate care. In this collaborative environment, the entire interprofessional healthcare team can direct therapy to its optimal result. [Level V]</p>
      </sec>
      <sec id="article-19927.s20">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=19927&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=19927">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/allergy/allergic-contact-dermatitis/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=19927">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/19927/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=19927">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-19927.s21">
        <fig id="article-19927.image.f1" position="float" orientation="portrait">
          <caption>
            <p>Contact Allergy From Band-Aid <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://dermnetnz.org/images">DermNet New Zealand</ext-link></p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="contact__allergy__bandaid" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-19927.s22">
        <fig id="article-19927.image.f2" position="float" orientation="portrait">
          <caption>
            <p>Contact Allergy From Nickel <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://dermnetnz.org/images">DermNet New Zealand</ext-link></p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="contact__allergy__nickel" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-19927.s23">
        <fig id="article-19927.image.f3" position="float" orientation="portrait">
          <caption>
            <p>Contact Allergy From Rubber <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://dermnetnz.org/images">DermNet New Zealand</ext-link></p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="contact__allergy__rubber" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-19927.s24">
        <fig id="article-19927.image.f4" position="float" orientation="portrait">
          <caption>
            <p>Classic presentation of nickel contact dermatitis involving lower abdomen and id reaction on elbows Contributed by Matilda Nicholas, MD, PhD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="IMG_0206" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-19927.s25">
        <fig id="article-19927.image.f5" position="float" orientation="portrait">
          <caption>
            <p>Contact dermatitis on arms after 72 hours of contact with poison ivy. Contributed by Wikimedia Commons, Larsonja (Public Domain)</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="1280px-Urushiol_induced_contact_dermatitis" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-19927.s26">
        <title>References</title>
        <ref id="article-19927.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Divkovic</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Pease</surname>
                <given-names>CK</given-names>
              </name>
              <name>
                <surname>Gerberick</surname>
                <given-names>GF</given-names>
              </name>
              <name>
                <surname>Basketter</surname>
                <given-names>DA</given-names>
              </name>
            </person-group>
            <article-title>Hapten-protein binding: from theory to practical application in the in vitro prediction of skin sensitization.</article-title>
            <source>Contact Dermatitis</source>
            <year>2005</year>
            <month>Oct</month>
            <volume>53</volume>
            <issue>4</issue>
            <fpage>189</fpage>
            <page-range>189-200</page-range>
            <pub-id pub-id-type="pmid">16191014</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19927.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lazzarini</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Mendon&#x000e7;a</surname>
                <given-names>RF</given-names>
              </name>
              <name>
                <surname>Hafner</surname>
                <given-names>MFS</given-names>
              </name>
            </person-group>
            <article-title>Allergic contact dermatitis to shoes: contribution of a specific series to the diagnosis.</article-title>
            <source>An Bras Dermatol</source>
            <year>2018</year>
            <season>Sep-Oct</season>
            <volume>93</volume>
            <issue>5</issue>
            <fpage>696</fpage>
            <page-range>696-700</page-range>
            <pub-id pub-id-type="pmid">30156619</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19927.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Aquino</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Rosner</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Systemic Contact Dermatitis.</article-title>
            <source>Clin Rev Allergy Immunol</source>
            <year>2019</year>
            <month>Feb</month>
            <volume>56</volume>
            <issue>1</issue>
            <fpage>9</fpage>
            <page-range>9-18</page-range>
            <pub-id pub-id-type="pmid">29766368</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19927.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lampel</surname>
                <given-names>HP</given-names>
              </name>
              <name>
                <surname>Powell</surname>
                <given-names>HB</given-names>
              </name>
            </person-group>
            <article-title>Occupational and Hand Dermatitis: a Practical Approach.</article-title>
            <source>Clin Rev Allergy Immunol</source>
            <year>2019</year>
            <month>Feb</month>
            <volume>56</volume>
            <issue>1</issue>
            <fpage>60</fpage>
            <page-range>60-71</page-range>
            <pub-id pub-id-type="pmid">30171459</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19927.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vocanson</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hennino</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rozi&#x000e8;res</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Poyet</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Nicolas</surname>
                <given-names>JF</given-names>
              </name>
            </person-group>
            <article-title>Effector and regulatory mechanisms in allergic contact dermatitis.</article-title>
            <source>Allergy</source>
            <year>2009</year>
            <month>Dec</month>
            <volume>64</volume>
            <issue>12</issue>
            <fpage>1699</fpage>
            <page-range>1699-714</page-range>
            <pub-id pub-id-type="pmid">19839974</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19927.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bock</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Said</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>M&#x000fc;ller</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Sch&#x000e4;fer-Korting</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Zoschke</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Weindl</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Characterization of reconstructed human skin containing Langerhans cells to monitor molecular events in skin sensitization.</article-title>
            <source>Toxicol In Vitro</source>
            <year>2018</year>
            <month>Feb</month>
            <volume>46</volume>
            <fpage>77</fpage>
            <page-range>77-85</page-range>
            <pub-id pub-id-type="pmid">28941582</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19927.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Esser</surname>
                <given-names>PR</given-names>
              </name>
              <name>
                <surname>Martin</surname>
                <given-names>SF</given-names>
              </name>
            </person-group>
            <article-title>Pathomechanisms of Contact Sensitization.</article-title>
            <source>Curr Allergy Asthma Rep</source>
            <year>2017</year>
            <month>Nov</month>
            <day>11</day>
            <volume>17</volume>
            <issue>12</issue>
            <fpage>83</fpage>
            <pub-id pub-id-type="pmid">29129023</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19927.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Signore</surname>
                <given-names>RJ</given-names>
              </name>
            </person-group>
            <article-title>Prevention of poison ivy dermatitis with oral homeopathic Rhus toxicodendron.</article-title>
            <source>Dermatol Online J</source>
            <year>2017</year>
            <month>Jan</month>
            <day>15</day>
            <volume>23</volume>
            <issue>1</issue>
            <pub-id pub-id-type="pmid">28329482</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19927.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Snyder</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Turrentine</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Cruz</surname>
                <given-names>PD</given-names>
              </name>
            </person-group>
            <article-title>Photocontact Dermatitis and Its Clinical Mimics: an Overview for the Allergist.</article-title>
            <source>Clin Rev Allergy Immunol</source>
            <year>2019</year>
            <month>Feb</month>
            <volume>56</volume>
            <issue>1</issue>
            <fpage>32</fpage>
            <page-range>32-40</page-range>
            <pub-id pub-id-type="pmid">29951786</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19927.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nicholson</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Brinsley</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Farooque</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Wakelin</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Patch testing with meropenem following a severe cutaneous adverse drug reaction.</article-title>
            <source>Contact Dermatitis</source>
            <year>2018</year>
            <month>Dec</month>
            <volume>79</volume>
            <issue>6</issue>
            <fpage>397</fpage>
            <page-range>397-398</page-range>
            <pub-id pub-id-type="pmid">30156311</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19927.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nguyen</surname>
                <given-names>HL</given-names>
              </name>
              <name>
                <surname>Yiannias</surname>
                <given-names>JA</given-names>
              </name>
            </person-group>
            <article-title>Contact Dermatitis to Medications and Skin Products.</article-title>
            <source>Clin Rev Allergy Immunol</source>
            <year>2019</year>
            <month>Feb</month>
            <volume>56</volume>
            <issue>1</issue>
            <fpage>41</fpage>
            <page-range>41-59</page-range>
            <pub-id pub-id-type="pmid">30145645</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19927.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Simonsen</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Foss-Skiftesvik</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Thyssen</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Deleuran</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mortz</surname>
                <given-names>CG</given-names>
              </name>
              <name>
                <surname>Zachariae</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Skov</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Osterballe</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Funding</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Avnstorp</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Andersen</surname>
                <given-names>BL</given-names>
              </name>
              <name>
                <surname>Vissing</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Danielsen</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Dufour</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Nielsen</surname>
                <given-names>NH</given-names>
              </name>
              <name>
                <surname>Thormann</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Sommerlund</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Johansen</surname>
                <given-names>JD</given-names>
              </name>
            </person-group>
            <article-title>Contact allergy in Danish children: Current trends.</article-title>
            <source>Contact Dermatitis</source>
            <year>2018</year>
            <month>Nov</month>
            <volume>79</volume>
            <issue>5</issue>
            <fpage>295</fpage>
            <page-range>295-302</page-range>
            <pub-id pub-id-type="pmid">30094861</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19927.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jaulent</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Dereure</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Raison-Peyron</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Contact dermatitis caused by polyacrylamide/C13-4 isoparaffin/laureth-7 mix in an emollient cream for atopic skin.</article-title>
            <source>Contact Dermatitis</source>
            <year>2019</year>
            <month>Jul</month>
            <volume>81</volume>
            <issue>1</issue>
            <fpage>70</fpage>
            <page-range>70-71</page-range>
            <pub-id pub-id-type="pmid">30684286</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19927.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Li</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Tao</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Bao</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Hua</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Jiang</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Hong</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Formononetin attenuated allergic diseases through inhibition of epithelial-derived cytokines by regulating E-cadherin.</article-title>
            <source>Clin Immunol</source>
            <year>2018</year>
            <month>Oct</month>
            <volume>195</volume>
            <fpage>67</fpage>
            <page-range>67-76</page-range>
            <pub-id pub-id-type="pmid">30077805</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19927.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Choi</surname>
                <given-names>FD</given-names>
              </name>
              <name>
                <surname>Juhasz</surname>
                <given-names>MLW</given-names>
              </name>
              <name>
                <surname>Atanaskova Mesinkovska</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Topical ketoconazole: a systematic review of current dermatological applications and future developments.</article-title>
            <source>J Dermatolog Treat</source>
            <year>2019</year>
            <month>Dec</month>
            <volume>30</volume>
            <issue>8</issue>
            <fpage>760</fpage>
            <page-range>760-771</page-range>
            <pub-id pub-id-type="pmid">30668185</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19927.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Luckett-Chastain</surname>
                <given-names>LR</given-names>
              </name>
              <name>
                <surname>Gipson</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Gillaspy</surname>
                <given-names>AF</given-names>
              </name>
              <name>
                <surname>Gallucci</surname>
                <given-names>RM</given-names>
              </name>
            </person-group>
            <article-title>Transcriptional profiling of irritant contact dermatitis (ICD) in a mouse model identifies specific patterns of gene expression and immune-regulation.</article-title>
            <source>Toxicology</source>
            <year>2018</year>
            <month>Dec</month>
            <day>01</day>
            <volume>410</volume>
            <fpage>1</fpage>
            <page-range>1-9</page-range>
            <pub-id pub-id-type="pmid">30171875</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
